- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01230489
The Efficacy of "MediHoney" to Facilitate Catheter Exit-Site Surgical Wound Healing
The Efficacy of "MediHoney" to Facilitate Catheter Exit-Site Surgical Wound Healing and Prevention of Wound Bacterial Colonization: A Randomized, Open-label, Controlled, Clinical Trial
Study Overview
Detailed Description
The exit site (ES) of any transcutaneous device, or foreign body, through the skin presents as the site most vulnerable in terms of device survival. With the large numbers of catheters in use in chronic dialysis today exit-site care for the prevention of infection is of critical importance in reducing morbidity and mortality. Pericatheter infection is the number one cause of catheter loss in peritoneal dialysis patients.
It appears that honey is a compound with a multi-factorial mode of action. It is thought that with most honeys, the antimicrobial action stems from its high osmolality and the fact that it produces continuous non-cytotoxic levels of hydrogen peroxide due to enzymatic break down of the sugar. Honey also has a low pH which is not conducive for most bacterial growth but is good for wound healing.
Observational reports have shown some success in healing infected wounds, ulcers, protection of plastic surgery transplants, burns, herpetic skin lesions, and atopic dermatitis. Honey has also been shown to have antimicrobial action against a broad spectrum of fungi and bacteria including antibiotic resistant bacteria. Another study reports that honey reduces inflammation, edema, and promotes angiogenesis.
In an animal study of urethral injury it was shown that contrary to controls, there was a total healing with restoration of normal urethral epithelium and connective tissue with complete absence of fibrosis and inflammation. There was also no narrowing of the lumen as seen in the other study groups.
A study of prophylactic exit-site care of hemodialysis catheters comparing honey and Mupirocin demonstrated that results with honey were comparable to that of Mupirocin. However, unlike Mupirocin, there has not been an emergence of honey-resistant bacterial strains which makes it an attractive alternative agent.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Missouri
-
Columbia, Missouri, United States, 65201
- University of Missouri Department of Medicine; Dialysis Clinic, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients requiring dialysis due to loss of kidney function
- Patients choosing Peritoneal Dialysis (PD) for treatment
- All PD patients having an indwelling PD catheter placed
Exclusion Criteria:
- Patients younger than 18 years of age
- Prisoners
- Patients with mental defect
- Veteran Administration patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Standard Care
This group will undergo the current standard of care for post operative exit sites at the involved institutions.
This group will act as the control or the group to which the interventional group will be compared too.
|
|
|
Experimental: MediHoney
This study group will have the dry 2 x 2 dressing replaced with a honey 2 x 2 dressing.
Additionally all indentations in the exit site wound will be filled with honey ointment prior to the application of the dressing.
|
In this group a Medihoney 2 x 2 will be used in place of the standard dry 2 x 2 currently used as the wound dressing.
Also all indentations of the wound will be filled with Medi-Honey ointment prior to the application of the dressing.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time From Catheter Implantation to First Exit Site Infection.
Time Frame: Two years
|
The outcome measure is the length of time from implantation until the patient has first exit site infection or two years which ever is shortest.
|
Two years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Harold L Moore, MA, University of Missouri, School of Medicine, Department of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1171097
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Failure
-
University of Sao Paulo General HospitalUnknownRenal Transplant Rejection | Graft Failure | Transplant; Failure, Kidney | Chronic Renal Failure (CRF)Brazil
-
Angiodynamics, Inc.TerminatedChronic Kidney Disease | Acute Kidney Injury | Acute Renal Failure | Renal Failure Chronic Contrast InducedUnited States
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Puerto Rico
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Canada
-
Washington University School of MedicineCompletedAcute Renal Failure | Chronic Renal FailureUnited States
-
University Hospital, GhentCompletedAcute Renal Failure | Chronic Renal FailureBelgium
-
The University of Hong KongHospital Authority, Hong KongCompletedEnd-stage Renal Failure (ESRF)Hong Kong
-
The Hong Kong Polytechnic UniversityHospital Authority, Hong KongCompletedPalliative Care | Renal Failure, End-stageHong Kong
-
PfizerCompletedChronic Renal Failure Requiring HemodialysisUnited States, Puerto Rico
-
Shenyang Sunshine Pharmaceutical Co., LTD.UnknownChronic Renal Failure With HemodialysisChina
Clinical Trials on MediHoney
-
Integra LifeSciences CorporationTerminated
-
Duke UniversityCompletedDiabetes Mellitus | Open Reduction External FixationUnited States
-
Allegheny Singer Research Institute (also known...Integra LifeSciences Corporation; West Virginia UniversityTerminated
-
HaEmek Medical Center, IsraelUnknownDisorder of Skin Donor SiteIsrael
-
Riyadh Elm UniversityUnknown
-
Soroka University Medical CenterCompletedAtopic DermatitisIsrael
-
University of Maryland, BaltimoreIntegra LifeSciences CorporationCompleted
-
Cyberjaya University College of Medical SciencesDiabetic Center-KFSHCompleted
-
Henry Ford Health SystemCompletedSkin InfectionUnited States
-
Icahn School of Medicine at Mount SinaiTerminated